Aetna Says ACA Is in “Death Spiral”
Amidst news of insurers pulling out from the 2018 exchanges, the Affordable Care Act (ACA) did not receive a vote of confidence from Aetna. Chief executive Mark Bertolini said the ACA’s exchanges are in a “death spiral” and predicted that many more plans would withdraw this year due to the “deteriorating” risk pool, according to a Washington Post article. Aetna sells exchange plans in only 4 states this year, and has not yet announced whether it will continue on the exchanges in 2018.
HHS Secretary Price Delays Drug Treatment Record Sharing Rule
About a month after the Obama administration released a final rule that would have made it easier for healthcare providers to share patients’ substance abuse treatment records with one another, HHS secretary Tom Price is pumping the brakes. The rule was supposed to take effect on Friday, but the date has now been pushed to March 21. A Federal Register notice explained that the delayed implementation is meant to allow sufficient time for public comments on the rule.
CMS Projects National Health Expenditure Growth
CMS has released a report that projects national health spending will rise by an average 5.6% annually until 2025, outpacing the projected growth in gross domestic product by 1.2 percentage points. The report attributes the growth to a more rapid pace of increase in medical prices. Lead author Sean Keehan anticipated that because of these cost pressures, “employers, insurers, and other payers will continue to pursue strategies that seek to effectively manage the use and cost of health care goods and services.”
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
Bustling Gene Therapy Pipeline for Neuromuscular Diseases Brings Thorny Questions to the Clinic
March 18th 2025The rapid development of gene therapy options for treating neuromuscular diseases has created new therapeutic options but also logistical hurdles and a need for complex discussions between clinicians and families.
Read More